Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Jasinski

Physician Assistant, Medical Norwalk, CT Physician Assistant

NPI 1598781791 CMS profile 10538931

761 Main Ave, Suite 102, Norwalk, CT 06851

Open in the dashboard

General payments

$185,159

1,186 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Jasinski of Norwalk, CT is reported in the CMS Open Payments database as having received $185,159 across 1,186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $64,535 362
2024 General $48,627 303
2023 General $36,589 262
2022 General $24,558 180
2021 General $10,849 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Jasinski
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to John Jasinski were reported at $64,535. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year John Jasinski Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $10,849 $156 $41–$563 $132
2022 $24,558 $185 $55–$649 $149
2023 $36,589 $199 $58–$717 $160
2024 $48,627 $206 $62–$740 $164
2025 $64,535 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $57,686 174 payments
  2. Incyte Corporation $36,111 129 payments
  3. UCB, Inc. $32,886 94 payments
  4. AbbVie, Inc. $17,439 192 payments
  5. Janssen Scientific Affairs, LLC $14,750 21 payments
  6. Sun Pharmaceutical Industries Inc. $9,064 58 payments
  7. Genzyme Corporation $3,166 71 payments
  8. Pfizer Inc. $2,873 52 payments
  9. LEO Pharma Inc. $2,225 55 payments
  10. Regeneron Healthcare Solutions, Inc. $1,916 91 payments
  11. Other $7,044 249 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $140,902 92 payments
  2. Food and Beverage $25,000 1,025 payments
  3. Travel and Lodging $9,371 54 payments
  4. Honoraria $4,875 4 payments
  5. Consulting Fee $4,605 6 payments
  6. Education $406 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $72,413 194 payments
  2. OPZELURA $34,829 127 payments
  3. Bimzelx $25,890 65 payments
  4. RINVOQ $13,661 75 payments
  5. ILUMYA $8,704 43 payments
  6. DUPIXENT Immunology $3,714 93 payments
  7. EUCRISA $2,778 47 payments
  8. Cimzia $2,074 24 payments
  9. DUPIXENT Immunology And Inflammation $1,966 30 payments
  10. DUPIXENT Inflammation And Immunology $1,265 60 payments
  11. Other $10,831 534 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,134

Median for Physician Assistant: 241

Drug cost

$205,367

Median for Physician Assistant: $4,110

Branded share of claims

8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 25 $93,750
Dupixent Pen Dupilumab Brand 22 $86,393
Doxycycline Hyclate Generic 35 $3,791
Halobetasol Propionate Generic 84 $3,530
Ketoconazole Generic 160 $2,606
Triamcinolone Acetonide Generic 150 $2,269
Minoxidil Generic 112 $1,689
Clobetasol Propionate Generic 41 $1,555
Metronidazole Generic 20 $1,128
Ciclopirox Generic 48 $1,037

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$157,735

Of which drugs: $4,610

Medicare patients

760

Average age 75

Services billed

3,828

322 women, 438 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 46%
Ischemic heart disease 26%
Diabetes 19%
Atrial fibrillation 18%
Cancer 18%
Depression 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 11 13 $3,939
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 18 18 $386
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 75 393 $285

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$18,641 — —
Bimzelx
$12,629 — —
OPZELURA
$12,460 — —
DUPIXENT
$775 47 —
ILUMYA
$643 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

1,186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record